Pathophysiology of thrombosis in myeloproliferative neoplasms

Raffaele Landolfi, Leonardo Di Gennaro

Risultato della ricerca: Contributo in rivistaArticolo in rivista

22 Citazioni (Scopus)


Life expectancy of patients with myeloproliferative neoplasms (MPNs) and particularly that of subjects with polycythemia vera (PV) and essential thrombocythemia (ET) has significantly increased over the last three decades, largely due to the use of cytoreductive treatments. Currently, polycythemia vera and essential thrombocythemia are considered relatively benign diseases in which the main objective of treatment strategy is the prevention of thrombotic events. Widespread use of routine hematologic screening and novel diagnostic tools greatly facilitate disease recognition and treatment.
Lingua originaleEnglish
pagine (da-a)183-186
Numero di pagine4
Stato di pubblicazionePubblicato - 2011


  • Myeloproliferative Disorders
  • Thrombosis


Entra nei temi di ricerca di 'Pathophysiology of thrombosis in myeloproliferative neoplasms'. Insieme formano una fingerprint unica.

Cita questo